TACSTD2 and gastric cancer: In gastric cancer, TROP2 promoted epithelial–mesenchymal transition (EMT) by interacting with β-catenin and increasing the expression of mesenchymal markers such as vimentin and fibronectin, while inhibiting E-cadherin expression.